DOCSLIB.ORG

Recommendation the 23Rd SEC (Antimicrobial & Anti-Viral)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recommendation the 23Rd SEC (Antimicrobial & Anti-Viral) Recommendation The 23rd SEC (Antimicrobial & Anti-Viral) meeting deliberated the proposals on 18-01-2016 and recommended the following: Agend File Name &Drug Firm Name Recommendation a name, Strength No New Drug Division 1 12-01/15-DC(Pt-120) Prof. Rup Lal Dr. Rup Lal presented the details of Rifamycin-B developmental work of Rifamycin-B Analogue analogue done by his team. The Committee opined that preclinical and clinical study should be conducted as per requirements of Schedule-Y of Drugs and Cosmetics Rules, 1945. 2 12-17/15-DC M/s. Astrazeneca The firm applied for permission to Ceftaroline Fosamil Pharma India Pvt. Ltd. Import and Market Ceftaroline Fosamil Injection (ZinfroTM) which is proposed to be indicated for the treatment of adult (≥ 18 years of age) patients with community-acquired pneumonia. The firm presented the Globhal Clinical Trial data on 200 Indian subjects of which 100 subjects were given Ceftaroline Fosamil. Earlier the proposal was deliberated in the SEC held on 22.06.2015 where the firm was asked to present the subset analysis with respect to safety and efficacy of the drug in Indian subjects. Now the firm presented the Indian data on safety and efficacy. Also the Committee noted that the drug is approved in USA since 2010 and also approved in EU, Australia, Asian countries etc. Therefore, the Committee recommended the Import and marketing of the drug Ceftaroline Fosamil indicated for the treatment of adult (≥ 18 years of age) patients with community-acquired pneumonia. GCT Division Proposal 3 CT/48/15 National Institute of Risk Versus Benefit to the Patients: MDR-TB Research in TB In light of the fact that the test drugs are old drugs and already marketed in the country, the safety profile of Page 1 of 5 23rdSEC-Antimicrobial, Antiviral, Antiparasitic, Antifungal, on 18.01.2016 Agend File Name &Drug Firm Name Recommendation a name, Strength No the test drugs justify the conduct of the trial. Innovation vis-a-vis Existing Therapeutic Option: The purpose of the study is the evaluation of a standard treatment regimen of anti- tuberculosis drugs for patients with MDR-TB for shortening of MDR-TB treatment. Unmet Medical Need in the Country: The test drugs may potentially provide alternate treatment regimens/ option in patients with MDR-TB. After detailed deliberation the committee noted that in a previous trial STREAM Stage 1, the applicant was asked to submit the safety data of moxifloxacin 800 mg. The applicant withdrew the proposal ( STREAM Stage 1). Now the applicant presented the protocol for STREAM Stage 2. During the presentation the applicant provided DSMB report which indicated that there is no major safety concern in STREAM Stage 1 trial wherein 154 patients are on 800 mg of moxifloxacin. After detailed deliberation the committee recommended conduct of the STREAM Stage 2 trial with following condition- 1. The no. of subject randomized to receive dose of 600 and 800 mg moxifloxacin should not exceed 10 for each dose. After 4 weeks of treatment with these doses, the applicant should present the safety data. After reviewing the data by the committee, decision for further enrolment in these doses will be considered while the treatment for already enrolled subject may be continued per Page 2 of 5 23rdSEC-Antimicrobial, Antiviral, Antiparasitic, Antifungal, on 18.01.2016 Agend File Name &Drug Firm Name Recommendation a name, Strength No protocol. 4 CT/51/15 M/s. BJ Medical Risk Versus Benefit to the Patients: Lopinavir/Ritonavir College, Pune. In light of the fact that the test drugs are old drugs and already marketed in the country, the safety profile of the test drugs justify the conduct of the trial. Innovation vis-a-vis Existing Therapeutic Option: The primary objective of the study is to assess HIV remission among HIV-infected neonates who initiate ART within 48 hours of birth. Unmet Medical Need in the Country: The study will provide essential data on whether early combination of antiretroviral therapy for high risk infants would achieve cure. After detailed deliberation the committee recommended the conduct of the study with the following conditions- 1. Adverse events should be closely monitored. 2. Children permanently discontinued from the study should be provided treatment/ referred to the NACO centre. FDC Division Proposal 5 4-11/2015-DC M/s Macleods The firm made a detailed Rifampicin+Isoniazid Pharmaceuticals presentation before the committee. 75mg+50mg DT The firm also presented the BE study data. The firm also claimed that the proposed formulation is already approved by Expert Review Panel of WHO. Committee was informed that FDC is already approved in other strength. The Committee noted that this FDC in proposed strength was also considered in meeting of Technical Committee for specification held on 13.03.2015.This FDC will be used in daily dosage regimen. The Page 3 of 5 23rdSEC-Antimicrobial, Antiviral, Antiparasitic, Antifungal, on 18.01.2016 Agend File Name &Drug Firm Name Recommendation a name, Strength No committee was informed that RNTCP has taken a policy decision for switching over from intermittent dosage regimen to daily dosage regimen for which this formulation has already been approved. Hence this Committee recommended for manufacturing and marketing for the proposed strength for pediatric and adolescents patients. 6 4-53/2008-DC(Pt. Aqua Vitoe FDC of Meropenem 1gm + Aqua) Laboratories Tazobactam 125mg/250mg injection Meropenam+Tazobact was earlier deliberated by the SEC in am its meeting held on 08.05.2015 1gm+125mg/250mg wherein committee suggested for submitting revised clinical trial protocol with certain modifications. However, instead of presenting revise protocol, the firm requested for waiver of clinical trial and made a presentation in this regard. The Committee noted that the firm did not present any additional data including clinical data on the proposed FDC to merit the trial waiver. Hence, the Committee rejected the request for the clinical trial waiver. 7 04-12/2015-DC M/s Macleods The firm made a detailed Rifampicin BP 75 Pharmaceuticals presentation before the committee. mg+Isoniazid BP The firm also presented the BE study 50mg + data. The firm also claimed that the Pyrazinamide- 150mg proposed formulation is already Dispersible tablets approved by Expert Review Panel of WHO. Committee was informed that FDC is already approved in other strength. The Committee noted that this FDC in proposed strength was also considered in meeting of Technical Committee for specification held on 13.03.2015.This FDC will be used in daily dosage regimen. The committee was informed that RNTCP has taken a policy decision for switching over from intermittent dosage regimen to daily dosage regimen for which this formulation Page 4 of 5 23rdSEC-Antimicrobial, Antiviral, Antiparasitic, Antifungal, on 18.01.2016 Agend File Name &Drug Firm Name Recommendation a name, Strength No has already been approved. Hence this Committee recommended for manufacturing and marketing for the proposed strength for pediatric and adolescents patients. SND Division 8 12-42/2015-DC(Pt- M/s Mylan The firm presented the proposal mylan-SND) before the committee. After Epinephrine deliberation the committee opined 0.3mg/0.3ml & that: epinephrine 1. Storage condition of the 0.15mg/0.3ml solution product is 20-25 degree for injection Celcius. Hence, stability data at 30C/65% RH is required to be submitted. 2. The usual recommended dose in adults is 0.3-0.5ml of 1mg/ml. The proposed strengths are 0.15-0.3ml of 1mg/ml which is on the lower side of the dosage schedule. Clarifications in this regard may be submitted by the firm. Medical Device Division 9 31-1405-MD/2013- M/s. Johnson & Firm did not turn up for presentation. DC BIOPATCH Johnson, Mumbai Protective Disc with CHG (Chlorhexidine) Page 5 of 5 23rdSEC-Antimicrobial, Antiviral, Antiparasitic, Antifungal, on 18.01.2016 .
Load more

Recommended publications
  • General Items
    Essential Medicines List (EML) 2019 Application for the inclusion of imipenem/cilastatin, meropenem and amoxicillin/clavulanic acid in the WHO Model List of Essential Medicines, as reserve second-line drugs for the treatment of multidrug-resistant tuberculosis (complementary lists of anti-tuberculosis drugs for use in adults and children) General items 1. Summary statement of the proposal for inclusion, change or deletion This application concerns the updating of the forthcoming WHO Model List of Essential Medicines (EML) and WHO Model List of Essential Medicines for Children (EMLc) to include the following medicines: 1) Imipenem/cilastatin (Imp-Cln) to the main list but NOT the children’s list (it is already mentioned on both lists as an option in section 6.2.1 Beta Lactam medicines) 2) Meropenem (Mpm) to both the main and the children’s lists (it is already on the list as treatment for meningitis in section 6.2.1 Beta Lactam medicines) 3) Clavulanic acid to both the main and the children’s lists (it is already listed as amoxicillin/clavulanic acid (Amx-Clv), the only commercially available preparation of clavulanic acid, in section 6.2.1 Beta Lactam medicines) This application makes reference to amendments recommended in particular to section 6.2.4 Antituberculosis medicines in the latest editions of both the main EML (20th list) and the EMLc (6th list) released in 2017 (1),(2). On the basis of the most recent Guideline Development Group advising WHO on the revision of its guidelines for the treatment of multidrug- or rifampicin-resistant (MDR/RR-TB)(3), the applicant considers that the three agents concerned be viewed as essential medicines for these forms of TB in countries.
    [Show full text]
  • Informatorium of COVID-19 Drugs in Indonesia" Has Been Compiled and Can Be Published Amidst the COVID-19 Outbreak in Indonesia
    THE INDONESIAN FOOD AND DRUG AUTHORITY INFORMATORIUM OF COVID-19 DRUGS IN INDONESIA THE INDONESIAN FOOD AND DRUG AUTHORITY MARCH 2020 1 INFORMATORIUM OF COVID-19 DRUGS IN INDONESIA THE INDONESIAN FOOD AND DRUG AUTHORITY ISBN 978-602-415-009-9 First Edition March 2020 COPYRIGHT PROTECTED BY LAW Reproduction of this book in part or whole, in any form and by any means, mechanically or electronically, including photocopies, records, and others without written permission from the publisher. This informatorium is based on information up to the time of publication and is subject to change if there is the latest data/information 2 3 FOREWORD Our praise and gratitude for the presence of God Almighty for His blessings and gifts, "The Informatorium of COVID-19 Drugs in Indonesia" has been compiled and can be published amidst the COVID-19 outbreak in Indonesia. As we know, the infections due to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) began to plague in December 2019 in Wuhan City, Hubei Province, People's Republic of China. The disease was caused by SARS-CoV-2 infection which was later known as Coronavirus Disease 2019 (COVID-19) which in early 2020 began to spread to several countries and eventually spread to almost all countries in the world. On March 11, 2020, WHO announced COVID-19 as a global pandemic. In Indonesia, the first case was officially announced on March 2, 2020. Considering that the spread of COVID-19 has been widespread and has an impact on social, economic, defense, and public welfare aspects in Indonesia, the President of the Republic of Indonesia established the Task Force for the Acceleration of COVID- 19 Handling aiming to increase readiness and ability to prevent, detect and respond to COVID-19.
    [Show full text]
  • Clinical Pharmacology and Biopharmaceutics Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) CLINICAL PHARMACOLOGY REVIEW NDA: 200-327 Submission Date(s): • 30 Dec 2009 (SDN 1) • 30 Apr 2010 (SDN 14) • 04 Feb 2010 (SDN 7) • 18 Jun 2010 (SDN 19) • 23 Apr 2010 (SDN 10) • 06 Aug 2010 (SDN 31) • 29 Apr 2010 (SDN 13) • 18 Aug 2010 (SDN 34) Drug Ceftaroline Fosamil for Injection Trade Name TEFLARO™ (proposed) OCP Reviewer Aryun Kim, Pharm.D. OCP Team Leader Charles Bonapace, Pharm.D. PM Reviewer Yongheng Zhang, Ph.D. PM Team Leader Pravin Jadhav, Ph.D. OCP Division DCP4 OND division DAIOP (520) Sponsor Cerexa, Inc., Oakland, CA Relevant IND(s) IND 71,371 Submission Type; Code Original New Drug Application (New Molecular Entity), 1S Formulation; Strength(s) Sterile (b) (4) of ceftaroline fosamil and L-arginine supplied as powder in single-use, 20-cc, clear, Type I glass vials containing 600 mg or 400 mg of ceftaroline fosamil Indication For the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible isolates of Gram-positive and Gram-negative microorganisms Dosage and 600 mg administered every 12 hours by intravenous infusion over 1 hour Administration in patients ≥18 years of age • for 5-14 days for treatment of cSSSI • for 5-7 days for treatment of CABP 1. EXECUTIVE SUMMARY 5 1.1 Recommendations 5 1.2 Phase 4 Commitments 6 1.3 Summary of Important Clinical Pharmacology and Biopharmaceutics Findings 6 2. QUESTION-BASED REVIEW 11 2.1 General Attributes of the Drug 11 2.2 General Clinical Pharmacology 13 2.3 Intrinsic Factors 37 2.4 Extrinsic Factors 56 2.5 General Biopharmaceutics 58 2.6 Analytical Section 58 3.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides
    Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides a, b,c Luke F. Chen, MBBS (Hons), MPH, CIC, FRACP *, Donald Kaye, MD KEYWORDS Rifaximin Pharmacokinetics Pharmacodynamics Toxicity Polymyxins Aminoglycoside Rifampin The polymyxins, rifamycins, and the aminoglycosides may be considered special use antibacterial agents. They are all old agents and are rarely considered the drugs of choice for common bacterial infections. The polymyxins are increasingly important because of the continued emergence of multidrug resistant (MDR) gram-negative organisms, such as strains of Pseudomonas aeruginosa or carbapenemase-producing Enterobacteriaceae that are susceptible to few remaining drugs. Rifampin is only considered in the context of nonmycobacterial infections where its role is limited and sometimes controversial. Rifaximin is a new enteric rifamycin that is increasingly used for gastrointestinal infections such as trav- eler’s diarrhea and Clostridium difficile infections (CDIs). This article will also review the current role of aminoglycosides in nonmycobacterial systemic infections, with an emphasis on the use of single daily administration. POLYMYXINS The polymyxins were discovered in 1947. Although there are five known polymyxin molecules, sequentially named polymyxin A through polymyxin E, only two polymyxins are available for therapeutic use: polymyxin B and polymyxin E (colistin) (Table 1). Both polymyxin B and polymyxin E are large cyclic cationic polypeptide detergents A version of this article appeared in the 23:4 issue of the Infectious Disease Clinics of North America. a Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Box 102359, Hanes House, Durham, NC 27710, USA b Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19102, USA c 1535 Sweet Briar Road, Gladwyne, PA 19035, USA * Corresponding author.
    [Show full text]
  • Treatment of Drug-Resistant Tuberculosis an Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R
    AMERICAN THORACIC SOCIETY DOCUMENTS Treatment of Drug-Resistant Tuberculosis An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R. Mase, Giovanni Battista Migliori, Giovanni Sotgiu, Graham H. Bothamley, Jan L. Brozek, Adithya Cattamanchi, J. Peter Cegielski, Lisa Chen, Charles L. Daley, Tracy L. Dalton, Raquel Duarte, Federica Fregonese, C. Robert Horsburgh, Jr., Faiz Ahmad Khan, Fayez Kheir, Zhiyi Lan, Alfred Lardizabal, Michael Lauzardo, Joan M. Mangan, Suzanne M. Marks, Lindsay McKenna, Dick Menzies, Carole D. Mitnick, Diana M. Nilsen, Farah Parvez, Charles A. Peloquin, Ann Raftery, H. Simon Schaaf, Neha S. Shah, Jeffrey R. Starke, John W. Wilson, Jonathan M. Wortham, Terence Chorba, and Barbara Seaworth; on behalf of the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America THIS OFFICIAL CLINICAL PRACTICE GUIDELINE WAS APPROVED BY THE AMERICAN THORACIC SOCIETY, THE EUROPEAN RESPIRATORY SOCIETY, AND THE INFECTIOUS DISEASES SOCIETY OF AMERICA SEPTEMBER 2019, AND WAS CLEARED BY THE U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION SEPTEMBER 2019 Background: The American Thoracic Society, U.S. Centers for was judged to be very low, because the data came Disease Control and Prevention, European Respiratory Society, and from observational studies with significant loss to follow-up Infectious Diseases Society of America jointly sponsored this new and imbalance in background regimens between comparator practice guideline on the treatment of drug-resistant tuberculosis groups. Good practices in the management of MDR-TB are (DR-TB). The document includes recommendations on the described. On the basis of the evidence review, a clinical strategy treatment of multidrug-resistant TB (MDR-TB) as well as tool for building a treatment regimen for MDR-TB is also isoniazid-resistant but rifampin-susceptible TB.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Publications 2016 – 2018
    PUBLICATIONS 2016 – 2018 (as reported in PubMed, to be updated annually) DEPARTMENT OF MEDICINE DIVISION OF ALLERGY, ASTHMA and IMMUNOLOGY Kevin Cook, MD Improvement in Asthma Control Using a Minimally Burdensome and Proactive Smartphone Application. Cook KA, Modena BD, Simon RA. J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):730-737.e1. doi: 10.1016/j.jaip.2016.03.005. Epub 2016 Apr 20. PMID:27107690 Rapid Aspirin Challenge in Patients with Aspirin Allergy and Acute Coronary Syndromes. Cook KA, White AA. Curr Allergy Asthma Rep. 2016 Feb;16(2):11. doi: 10.1007/s11882-015-0593-2. Review. PMID:26758864 Increased risk of systemic reactions extends beyond completion of rush immunotherapy. Cook KA, Kelso JM, White AA. J Allergy Clin Immunol Pract. 2017 Nov - Dec;5(6):1773-1775. doi: 10.1016/j.jaip.2017.04.015. Epub 2017 May 11. No abstract available. PMID: 28506424 Use of a composite symptom score during challenge in patients with suspected aspirin-exacerbated respiratory disease. Cook KA, Modena BD, Wineinger NE, Woessner KM, Simon RA, White AA. Ann Allergy Asthma Immunol. 2017 May;118(5):597-602. doi: 10.1016/j.anai.2017.02.016. PMID: 28477789 Half of systemic reactions to allergen immunotherapy are delayed, majority require treatment with epinephrine. Cook KA, Ford CM, Leyvas EA, Waalen J, White AA. J Allergy Clin Immunol Pract. 2017 Sep - Oct;5(5):1415-1417. doi: 10.1016/j.jaip.2017.03.025. Epub 2017 Apr 25. No abstract available. PMID:28454684 A 30-year-old woman with chronic hives, intermittent fevers, and joint pain.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Frequently Asked Questions on The
    Frequently asked questions on the WHO treatment guidelines for isoniazid-resistant tuberculosis Version: 24 April 2018 The advice in this document has been prepared by the Global TB Programme of the World Health Organization (WHO) and is to be read alongside the WHO treatment guidelines for isoniazid-resistant tuberculosis and its online annexes. See Further reading ​ ​ at end for additional resources. Who are the new WHO treatment guidelines for isoniazid-resistant tuberculosis intended for ? ​ ​ The WHO treatment guidelines for isoniazid-resistant tuberculosis are targeted at health care ​ professionals (doctors, nurses) and other staff involved in TB care in both low and high resource settings. The possibility of drug-resistant disease now needs to be entertained whenever treating TB patients. These guidelines provide technical detail which is helpful in making the best-informed decision in clinical practice and programme management. The answers to the frequently asked questions (FAQ) in this document intend to help implementers with common, practical issues that arise when adopting the new guidance. This document complements the WHO guidelines by elaborating further on certain aspects of ​ implementation that were beyond the scope of the guideline itself. What are the main recommendations of these new guidelines ? The new guidelines recommend that patients with confirmed isoniazid-resistant and rifampicin susceptible tuberculosis (abbreviated to Hr-TB) are treated for 6 months with a regimen composed of ​ ​ rifampicin (R), ethambutol (E), pyrazinamide (Z) and levofloxacin (Lfx). The exclusion of rifampicin resistance ahead of start of this regimen is critical. It is further recommended not to add streptomycin (S) or other injectable agents to the treatment regimen.
    [Show full text]
  • Swedres Svarm 2012
    2012 SWEDRES|SVARM Swedish Antibiotic Utilisation and Resistance in Human Medicine Swedish Veterinary Antimicrobial Resistance Monitoring 2 SWEDRES |SVARM 2012 A Report on Swedish Antibiotic Utilisation and Resistance in Human Medicine (SWEDRES) and Swedish Veterinary Antimicrobial Resistance Monitoring (SVARM) Published by: Swedish Institute for Communicable Disease Control and National Veterinary Institute Editors: Jenny Hellman and Barbro Olsson-Liljequist, Swedish Institute for Communicable Disease Control Björn Bengtsson and Christina Greko, National Veterinary Institute Addresses: The Swedish Institute for Communicable Disease Control SE-171 82 Solna, Sweden Phone: +46 (0) 8 457 23 00 Fax: +46 (0) 8 328330 E-mail: [email protected] www.smi.se The National Veterinary Institute SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] www.sva.se Article number 2013-101-1 ISSN 1650-6332 This title and previous SWEDRES and SVARM reports are available for downloading at www.smi.se/publikationer or www.sva.se This title can be ordered from: Smittskyddsinstitutets beställningsservice c/o Strömberg, 120 88 Stockholm Fax: +46 (0) 8 – 779 96 67 E-mail: [email protected] Department of Animal Health and Antimicrobial Strategies, National Veterinary Institute SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] Text and tables may be cited and reprinted only with refer- ence to this report. Images, photographs and illustrations are protected by copyright. Suggested citation: SWEDRES-SVARM 2012. Use of antimicrobials and occur- rence of antimicrobial resistance in Sweden.
    [Show full text]
  • Anti-Infective Drug Poster
    Anti-Infective Drugs Created by the Njardarson Group (The University of Arizona): Edon Vitaku, Elizabeth A. Ilardi, Daniel J. Mack, Monica A. Fallon, Erik B. Gerlach, Miyant’e Y. Newton, Angela N. Yazzie, Jón T. Njarðarson Streptozol Spectam Novocain Sulfadiazine M&B Streptomycin Chloromycetin Terramycin Tetracyn Seromycin Tubizid Illosone Furadantin Ethina Vancocin Polymyxin E Viderabin Declomycin Sulfamethizole Blephamide S.O.P. ( Sulfanilamide ) ( Spectinomycin ) ( Procaine ) ( Sulfadiazine ) ( Sulfapyridine ) ( Streptomycin ) ( Chloramphenicol ) ( Oxytetracycline ) ( Tetracycline ) ( Cycloserine ) ( Isoniazid ) ( Erythromycin ) ( Nitrofurantoin ) ( Ethionamide ) ( Vancomycin ) ( Colistin ) ( Vidarabine ) ( Demeclocycline ) ( Sulfamethizole ) ( Prednisolone Acetate & Sulfacetamide ) ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIMYCOBACTERIAL ANTIMYCOBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIMYCOBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIVIRAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL Approved 1937 Approved 1937 Approved 1939 Approved 1941 Approved 1942 Approved 1946 Approved 1949 Approved 1950 Approved 1950s Approved 1950s Approved 1952 Approved 1953 Approved 1953 Approved 1956 Approved 1958 Approved 1959 Approved 1960 Approved 1960 Approved 1960s Approved 1961 Coly-Mycin S Caprocin Poly-Pred Aureocarmyl Stoxil Flagyl NegGram Neomycin Flumadine Omnipen Neosporin G.U. Clomocycline Versapen-K Fungizone Vibramycin Myambutol Pathocil Cleocin Gentak Floxapen
    [Show full text]